Downregulation of AKT3 Increases Migration and Metastasis in Triple Negative Breast Cancer Cells by Upregulating S100A4

Background Treatment of breast cancer patients with distant metastases represents one of the biggest challenges in today’s gynecological oncology. Therefore, a better understanding of mechanisms promoting the development of metastases is of paramount importance. The serine/threonine kinase AKT was shown to drive cancer progression and metastasis. However, there is emerging data that single AKT isoforms (i.e. AKT1, AKT2 and AKT3) have different or even opposing functions in the regulation of cancer cell migration in vitro, giving rise to the hypothesis that inhibition of distinct AKT isoforms might have undesirable effects on cancer dissemination in vivo. Methods The triple negative breast cancer cell line MDA-MB-231 was used to investigate the functional roles of AKT in migration and metastasis. AKT single and double knockdown cells were generated using isoform specific shRNAs. Migration was analyzed using live cell imaging, chemotaxis and transwell assays. The metastatic potential of AKT isoform knockdown cells was evaluated in a subcutaneous xenograft mouse model in vivo. Results Depletion of AKT3, but not AKT1 or AKT2, resulted in increased migration in vitro. This effect was even more prominent in AKT2,3 double knockdown cells. Furthermore, combined downregulation of AKT2 and AKT3, as well as AKT1 and AKT3 significantly increased metastasis formation in vivo. Screening for promigratory proteins revealed that downregulation of AKT3 increases the expression of S100A4 protein. In accordance, depletion of S100A4 by siRNA approach reverses the increased migration induced by knockdown of AKT3. Conclusions We demonstrated that knockdown of AKT3 can increase the metastatic potential of triple negative breast cancer cells. Therefore, our results provide a rationale for the development of AKT isoform specific inhibitors.

[1]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[2]  J. Petrik,et al.  Opposing Functions of Akt Isoforms in Lung Tumor Initiation and Progression , 2014, PloS one.

[3]  Y. Mo,et al.  The Akt-associated microRNAs , 2012, Cellular and Molecular Life Sciences.

[4]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[5]  A. Toker,et al.  Akt isoform-specific signaling in breast cancer , 2011, Cell adhesion & migration.

[6]  J. Rantala,et al.  Distinct roles of AKT isoforms in regulating β1-integrin activity, migration, and invasion in prostate cancer , 2012, Molecular biology of the cell.

[7]  R. Vessella,et al.  Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of β(1,6)-Branched Oligosaccharides as a Marker of Tumor Progression , 2012, Clinical Cancer Research.

[8]  T. Northen,et al.  Unraveling heterogeneous susceptibility and the evolution of breast cancer using a systems biology approach , 2015, Genome Biology.

[9]  A. Jemal,et al.  Breast Cancer Statistics , 2013 .

[10]  W. Neuhofer,et al.  NFAT5-mediated expression of S100A4 contributes to proliferation and migration of renal carcinoma cells , 2014, Front. Physiol..

[11]  Tao Yang,et al.  Nuclear factor of activated T cells 5 maintained by Hotair suppression of miR-568 upregulates S100 calcium binding protein A4 to promote breast cancer metastasis , 2014, Breast Cancer Research.

[12]  H. Kwon,et al.  Tonicity-independent regulation of the osmosensitive transcription factor TonEBP (NFAT5). , 2012, American journal of physiology. Cell physiology.

[13]  J. Field,et al.  Isoform-specific functions of Akt in cell motility , 2007, Cellular and Molecular Life Sciences.

[14]  E. Horn,et al.  Chemotaxis of slow migrating mammalian cells analysed by video microscopy. , 2011, Methods in molecular biology.

[15]  HighWire Press,et al.  American journal of physiology. Cell physiology , 1977 .

[16]  K. Pantel,et al.  Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. , 2011, Cellular signalling.

[17]  J. Brugge,et al.  Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition , 2005, The Journal of cell biology.

[18]  R. Figlin,et al.  Akt inhibitors in clinical development for the treatment of cancer , 2010, Expert opinion on investigational drugs.

[19]  T. McGraw,et al.  The Akt kinases: Isoform specificity in metabolism and cancer , 2009, Cell cycle.

[20]  J. Vadgama,et al.  Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer , 2008, Breast Cancer Research.

[21]  R. Hansen,et al.  Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. , 2002, Journal of the National Cancer Institute.

[22]  J. Massagué,et al.  Review Origins of Metastatic Traits , 2022 .

[23]  Lei Shi,et al.  Hepatocellular carcinoma‐associated mesenchymal stem cells promote hepatocarcinoma progression: Role of the S100A4‐miR155‐SOCS1‐MMP9 axis , 2013, Hepatology.

[24]  A. Toker,et al.  Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. , 2005, Molecular cell.

[25]  Leigh-Ann MacFarlane,et al.  MicroRNA: Biogenesis, Function and Role in Cancer , 2010, Current genomics.

[26]  Kevin Struhl,et al.  MicroRNAs Differentially Regulated by Akt Isoforms Control EMT and Stem Cell Renewal in Cancer Cells , 2009, Science Signaling.

[27]  Leslie M. Shaw,et al.  The role of NFAT transcription factors in integrin-mediated carcinoma invasion , 2002, Nature Cell Biology.

[28]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[29]  Yu Liang,et al.  S100A4 promotes invasion and angiogenesis in breast cancer MDA-MB-231 cells by upregulating matrix metalloproteinase-13. , 2012, Acta biochimica Polonica.

[30]  Q. Xue,et al.  Akt1 and akt3 exert opposing roles in the regulation of vascular tumor growth. , 2014, Cancer research.

[31]  A. Toker,et al.  Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. , 2009, Cellular signalling.

[32]  Thomas Tuschl,et al.  MicroRNAs in human cancer. , 2013, Advances in experimental medicine and biology.

[33]  Terry L. Smith,et al.  Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers , 2004, Clinical Cancer Research.

[34]  A. Bresnick,et al.  Integrin α6β4 Controls the Expression of Genes Associated with Cell Motility, Invasion, and Metastasis, Including S100A4/Metastasin* , 2009, Journal of Biological Chemistry.

[35]  G. Calin,et al.  Expression, Tissue Distribution and Function of miR-21 in Esophageal Squamous Cell Carcinoma , 2013, PloS one.

[36]  Keith R. Johnson,et al.  N-Cadherin Promotes Motility in Human Breast Cancer Cells Regardless of Their E-Cadherin Expression , 1999, The Journal of cell biology.

[37]  A. Jemal,et al.  Breast cancer statistics, 2013 , 2014, CA: a cancer journal for clinicians.

[38]  Min Chen,et al.  Src kinase pathway is involved in NFAT5-mediated S100A4 induction by hyperosmotic stress in colon cancer cells. , 2011, American journal of physiology. Cell physiology.

[39]  S. Chung,et al.  N-cadherin regulates mammary tumor cell migration through Akt3 suppression , 2013, Oncogene.

[40]  J E Paciga,et al.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. , 2001, The American journal of pathology.

[41]  Aleix Prat Aparicio Comprehensive molecular portraits of human breast tumours , 2012 .

[42]  W. Muller,et al.  Distinct biological roles for the akt family in mammary tumor progression. , 2010, Cancer research.

[43]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[44]  Andrew H. Beck,et al.  Targeting Akt3 signaling in triple-negative breast cancer. , 2014, Cancer research.

[45]  David Olmos,et al.  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Yibin Kang,et al.  Tumor cell dissemination: emerging biological insights from animal models and cancer patients. , 2013, Cancer cell.

[47]  Hong Wang,et al.  Inhibitory phosphorylation of GSK-3β by AKT, PKA, and PI3K contributes to high NaCl-induced activation of the transcription factor NFAT5 (TonEBP/OREBP). , 2013, American journal of physiology. Renal physiology.

[48]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[49]  Qianjun Li,et al.  S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase , 2015, Scientific Reports.

[50]  Chang Nam Kim,et al.  Enhanced S100A4 protein expression is clinicopathologically significant to metastatic potential and p53 dysfunction in colorectal cancer. , 2009, Oncology reports.

[51]  M. Belvin,et al.  Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models , 2010, Clinical Cancer Research.

[52]  A. Horii,et al.  S100A4 is frequently overexpressed in lung cancer cells and promotes cell growth and cell motility. , 2014, Biochemical and biophysical research communications.

[53]  K. B. Pedersen,et al.  Expression of S100A4, E-cadherin, α- and β-catenin in breast cancer biopsies , 2002, British Journal of Cancer.

[54]  J. Peterse,et al.  Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.

[55]  J. Rantala,et al.  451 Distinct Roles of AKT Isoforms in Regulating Beta1-integrin Activity, Migration and Invasion in Prostate Cancer , 2012 .

[56]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[57]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.